These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 37071496)

  • 1. Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model.
    Chen SS; Barrientos JC; Ferrer G; King-Richards M; Chen YJ; Ravichandran P; Ibrahim M; Kieso Y; Waters S; Kutok JL; Peluso M; Sharma S; Weaver DT; Pachter JA; Rai KR; Chiorazzi N
    Clin Cancer Res; 2023 May; 29(10):1984-1995. PubMed ID: 37071496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noncatalytic Bruton's tyrosine kinase activates PLCγ
    Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
    J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.
    Wiśniewski K; Puła B
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells.
    Arthur R; Wathen A; Lemm EA; Stevenson FK; Forconi F; Linley AJ; Steele AJ; Packham G; Valle-Argos B
    Cell Signal; 2022 Aug; 96():110358. PubMed ID: 35597428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.
    Smith CIE; Burger JA
    Front Immunol; 2021; 12():689472. PubMed ID: 34177947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy.
    Nikolaenko L; Liu T; Danilov AV
    Expert Rev Anticancer Ther; 2021 May; 21(5):481-488. PubMed ID: 33499685
    [No Abstract]   [Full Text] [Related]  

  • 8. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
    Kapoor I; Li Y; Sharma A; Zhu H; Bodo J; Xu W; Hsi ED; Hill BT; Almasan A
    Cell Death Dis; 2019 Dec; 10(12):924. PubMed ID: 31801949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duvelisib for the treatment of chronic lymphocytic leukemia.
    Frustaci AM; Tedeschi A; Deodato M; Zamprogna G; Cairoli R; Montillo M
    Expert Opin Pharmacother; 2020 Aug; 21(11):1299-1309. PubMed ID: 32292084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening and monitoring of the BTK
    Bödör C; Kotmayer L; László T; Takács F; Barna G; Kiss R; Sebestyén E; Nagy T; Hegyi LL; Mikala G; Fekete S; Farkas P; Balogh A; Masszi T; Demeter J; Weisinger J; Alizadeh H; Kajtár B; Kohl Z; Szász R; Gergely L; Gurbity Pálfi T; Sulák A; Kollár B; Egyed M; Plander M; Rejtő L; Szerafin L; Ilonczai P; Tamáska P; Pettendi P; Lévai D; Schneider T; Sebestyén A; Csermely P; Matolcsy A; Mátrai Z; Alpár D
    Br J Haematol; 2021 Jul; 194(2):355-364. PubMed ID: 34019713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.
    Vangapandu HV; Jain N; Gandhi V
    Expert Opin Investig Drugs; 2017 May; 26(5):625-632. PubMed ID: 28388280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies.
    Kapoor I; Bodo J; Hill BT; Almasan A
    Cell Death Dis; 2021 Nov; 12(11):1061. PubMed ID: 34750354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance.
    Blombery P; Thompson ER; Lew TE; Tiong IS; Bennett R; Cheah CY; Lewis KL; Handunnetti SM; Tang CPS; Roberts A; Seymour JF; Tam CS
    Blood Adv; 2022 Oct; 6(20):5589-5592. PubMed ID: 35901282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.
    Shadman M
    JAMA; 2023 Mar; 329(11):918-932. PubMed ID: 36943212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
    Naeem A; Utro F; Wang Q; Cha J; Vihinen M; Martindale S; Zhou Y; Ren Y; Tyekucheva S; Kim AS; Fernandes SM; Saksena G; Rhrissorrakrai K; Levovitz C; Danysh BP; Slowik K; Jacobs RA; Davids MS; Lederer JA; Zain R; Smith CIE; Leshchiner I; Parida L; Getz G; Brown JR
    Blood Adv; 2023 May; 7(9):1929-1943. PubMed ID: 36287227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
    Till KJ; Pettitt AR; Slupsky JR
    J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib.
    Catania G; Tavarozzi R; Pini GM; Borra T; Gandolfo C; Zacchi G; Pietrasanta D; Monaco F; Zanni M; Lettieri M; Rivela P; Zallio F; Ladetto M
    J Basic Clin Physiol Pharmacol; 2023 May; 34(3):401-404. PubMed ID: 37040263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Japanese phase Ib study of the oral PI3K-δ and -γ inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Makita S; Ota S; Mishima Y; Usuki K; Ennishi D; Yanada M; Fukuhara N; Yamamoto R; Takamine A; Nohara G; Izutsu K
    Int J Hematol; 2024 Feb; 119(2):156-163. PubMed ID: 38150138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
    Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
    Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.